We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Prognostic significance of Ki67 in Chinese women diagnosed with ER + /HER2 - breast cancers by the 2015 St. Gallen consensus classification.
BMC Cancer 2017 January 7
BACKGROUND: This study evaluated the distribution pattern of the Ki67-labeling index (LI) among patients at a Chinese breast cancer center, and analyzed its prognostic significance in the 2015 St Gallen consensus breast cancer classification, estrogen receptor-positive and human epidermal growth factor receptor 2-negative(ER+ /HER2- )subtype.
METHODS: We classified 939 women with ER+ /HER2- breast cancer into three groups by Ki67-LI levels, and followed their clinicopathologic characteristics and prognoses.
RESULTS: In the 939 eligible subjects, 342 had Ki67-LI ≤10% (Ki67Low ), 281 had Ki67-LI between 10 and 30% (Ki67Medium ), and 316 had Ki67-LI ≥30% (Ki67High ). Although the Ki67High group had less favorable clinicopathologic factors, the Ki67Medium group's factors varied considerably. Kaplan-Meier estimates showed that disease-free survival(DFS) for the Ki67Medium group was significantly shorter than the Ki67Low group but longer than the Ki67High group. Ki67-LI had independent prognostic significance in multivariate analysis. Other diagnostic factors, including tumor size >2 cm, positive lymph nodes, and grade III disease, were significantly associated with poorer disease-free survival only in the Ki67Medium group.
CONCLUSIONS: For patients with ER+ /HER2- breast cancer, we confirmed three distinct risk patterns by Ki67-LI levels according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information.
METHODS: We classified 939 women with ER+ /HER2- breast cancer into three groups by Ki67-LI levels, and followed their clinicopathologic characteristics and prognoses.
RESULTS: In the 939 eligible subjects, 342 had Ki67-LI ≤10% (Ki67Low ), 281 had Ki67-LI between 10 and 30% (Ki67Medium ), and 316 had Ki67-LI ≥30% (Ki67High ). Although the Ki67High group had less favorable clinicopathologic factors, the Ki67Medium group's factors varied considerably. Kaplan-Meier estimates showed that disease-free survival(DFS) for the Ki67Medium group was significantly shorter than the Ki67Low group but longer than the Ki67High group. Ki67-LI had independent prognostic significance in multivariate analysis. Other diagnostic factors, including tumor size >2 cm, positive lymph nodes, and grade III disease, were significantly associated with poorer disease-free survival only in the Ki67Medium group.
CONCLUSIONS: For patients with ER+ /HER2- breast cancer, we confirmed three distinct risk patterns by Ki67-LI levels according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app